Formula I Compounds for Tyrosine Kinase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, especially for metastatic disease, are largely palliative and offer limited long-term cures, with existing chemotherapies improving patient survival by only months rather than years, highlighting a need for more effective drugs that can treat cell proliferation disorders effectively as both first-line and second/third-line therapies.
Innovation Solution
Development of specific compounds, including those of Formula I and their salts, solvates, hydrates, and prodrugs, which act as anti-proliferative agents, targeting tyrosine kinase inhibition to treat cancers such as lung and breast cancer, and other cell proliferation disorders by modulating kinase pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current chemotherapies are used to treat metastatic cancer, then patient survival is improved by months, but the treatment remains palliative and seldom offers long-term cures
Solution Approach 1:
The patent applies parameter changes by developing compounds with novel chemical structures (Formula I) that exhibit improved pharmacological properties compared to existing chemotherapies. The compounds are designed to optimize binding affinity to target kinases, improve selectivity, and enhance therapeutic index, thereby transforming palliative treatment into potentially curative therapy with sustained survival benefits.
Solution Approach 2:
The patent employs structure-based drug design by creating compounds that replicate and optimize the binding interactions of known kinase inhibitors while introducing novel structural features. The compounds of Formula I are designed to copy successful pharmacophore elements from existing drugs while eliminating their limitations, achieving both prolonged survival and improved cure rates.
2Duration of action of moving object
If new chemotherapies are developed to improve patient survival by years, then long-term cures may be achieved, but the need remains for new drugs effective in combination with existing agents and for resistant tumors
Solution Approach 1:
The patent achieves universality by designing compounds of Formula I with broad-spectrum kinase inhibitory activity that can effectively target multiple cancer types and resistance mechanisms. The compounds are engineered to inhibit both ATP-competitive and ATP-noncompetitive kinases, making them suitable for use as first-line therapy in combination with existing agents and as second/third-line therapies for resistant tumors, thereby providing multi-functional efficacy across different treatment scenarios.
3Reliability
If compounds are designed to inhibit tyrosine kinase pathways, then cell proliferation disorders can be treated, but specificity and selectivity of inhibition must be maintained to avoid off-target effects
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions in the compound structure (Formula I). The R1-R6 substituents are carefully selected to optimize binding to the ATP-binding pocket of target kinases while preventing interaction with off-target proteins. This localized structural optimization ensures high specificity for tyrosine kinase inhibition while maintaining therapeutic efficacy and minimizing harmful off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate potential as effective pharmaceutical agents in treating various cancers and cell proliferation disorders by inhibiting tyrosine kinases like Src kinase and focal adhesion kinase, offering a new approach to improving patient outcomes beyond current chemotherapy limitations.
Implementation Method 1
The compounds of the invention are useful in treating diseases and disorders that are modulated by tyrosine kinase inhibition. For example, the compounds of the invention are useful in treating diseases and disorders that are modulated by Src kinase. The compounds of the invention may also be useful in treating diseases and disorders that are modulated by focal adhesion kinase (FAK).
Data Source
AI summary
The invention relates to compounds and methods for treating cell proliferation disorders.